Skip to main content
. 2023 Aug 1;18:37. doi: 10.1186/s13006-023-00576-y

Table 4.

Differences in breastfeeding and non-breastfeeding mothers with SLE 6 months after delivery

N Breastfeeding
N = 44
N Non-breastfeeding
N = 38
p-valuea
Age ≥ 35 years, (%) 44 18.2 38 36.8 0.08
BMI (kg/m2), mean (SD) 36 25.6 (5.6) 26 24.3 (5.5) 0.26
 Overweight (≥ 25 kg/m2) 17 (47.2) 9 (34.6) 0.44
Work status (full -or parttime), (%) 39 7.7 27 11.1 0.68
VAS scores (0–100), median (IQR) 27 21
 Pain 24 (8–40) 20 (0–49) 0.88
 Fatigue 26 (3–50) 30 (5- 63) 0.62
 Global score 12 (3–37) 25 (8–55) 0.23
Inflammatory active diseaseb (%) 36 5.6 23 4.3 1.00
CRP value (mg/L), mean (SD) 37 2.30 (2.2) 26 2.7 (3.1) 0.81
Regular physical activityc (%) 18 66.7 21 61.9 1.00
Medications, n (%) 44 38
 HCQ 34 (77.3) 28 (73.7) 0.80
 sDMARDd 16 (36.4) 13 (34.2) 1.00
 bDMARDe 0 1 (2.6) -

SD standard deviation, BMI body mass index, CRP C-reactive protein, VAS visual analog scale, IQR interquartile range, HCQ hydroxychloroquine, sDMARDs synthetic disease modifying anti-rheumatic drugs, bDMARDs biologic disease modifying anti-rheumatic drugs

agroup comparisons were performed using Fisher´s exact test for categorical variables and independent samples t-test for continuous, normally distributed variables. For ordinal and continuous, non-normally distributed data Mann Whitney U test was performed

bmeasured by LAI-P/SLEDAI. Active disease: ≥ 2,2 (LAI-P) or > 6 (SLEDAI)

cat least once weekly

d sDMARDs included azathioprine, methotrexate, sulphasalazine and mycophenolate mofetil

ebDMARDs included belimumab, TNF-inhibitors and interleukin inhibitors